NCT00842309

D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder

A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to conduct a double-blind, placebo-controlled study of D-cycloserine (DCS) augmentation of behavior therapy in individuals with Body Dysmorphic Disorder (BDD). Specifically, we intend to randomize 50 individuals with BDD to receive either DCS (n = 25) or placebo (n = 25) one hour prior to 8 of 10 behavior therapy sessions.

Conditions

• Body Dysmorphic Disorder

Interventions

Type	Name	Description
DRUG	d-cycloserine	100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
DRUG	Placebo	Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.

Timeline

• Start date: 2008-11-01
• Primary completion: 2017-12-01
• Completion: 2018-08-01
• First posted: 2009-02-12
• Last updated: 2019-06-18
• Results posted: 2019-03-15

Locations

1 site across 1 country: United States